COSCIENS Biopharma annual free cash flow
2015
2016
2017
2018
2021
2022
2023
2024
2025
COSCIENS Biopharma Free Cash Flow (FCF) History (CSCIF)
COSCIENS Biopharma reported −$9.2M in free cash flow for fiscal 2025, an increase of $6.5M from the previous fiscal year, with a free cash flow margin of −122.42%.
View full COSCIENS Biopharma company overviewCOSCIENS Biopharma free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.2M | $6.5M | — | −122.42% |
| 2024 | 2024-12-31 | −$15.7M | −$12.4M | — | −164.07% |
| 2023 | 2023-12-31 | −$3.3M | −$8.2M | — | −46.26% |
| 2022 | 2022-12-31 | $4.9M | $13.5M | — | +33.80% |
| 2021 | 2021-12-31 | −$8.6M | −$15.4M | — | −163.71% |
| 2018 | 2018-12-31 | $6.8M | $29.7M | — | +25.36% |
| 2017 | 2017-12-31 | −$22.9M | $6.2M | — | −2482.88% |
| 2016 | 2016-12-31 | −$29.1M | $4.8M | — | −3191.66% |
| 2015 | 2015-12-31 | −$33.9M | — | — | −6214.68% |
COSCIENS Biopharma quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$1.5M | $1.8M | — | −85.84% |
| Q3 2025 | 2025-09-30 | −$680,000 | $7.2M | — | −45.85% |
| Q2 2025 | 2025-06-30 | −$4.5M | −$3.0M | — | −163.55% |
| Q1 2025 | 2025-03-31 | −$2.5M | $449,000 | — | −166.33% |
| Q4 2024 | 2024-12-31 | −$3.3M | −$4.9M | — | −100.21% |
| Q3 2024 | 2024-09-30 | −$7.9M | −$8.0M | — | −422.77% |
| Q2 2024 | 2024-06-30 | −$1.5M | −$679,000 | — | −66.15% |
| Q1 2024 | 2024-03-31 | −$2.9M | $1.1M | — | −143.12% |
| Q4 2023 | 2023-12-31 | $1.5M | −$13.7M | −89.95% | +91.68% |
| Q3 2023 | 2023-09-30 | $94,000 | $4.0M | — | +4.82% |
| Q2 2023 | 2023-06-30 | −$867,000 | $4.0M | — | −62.28% |
| Q1 2023 | 2023-03-31 | −$4.1M | −$2.6M | — | −190.93% |
| Q4 2022 | 2022-12-31 | $15.2M | $17.7M | — | +133.47% |
| Q3 2022 | 2022-09-30 | −$4.0M | −$2.5M | — | −212.58% |
| Q2 2022 | 2022-06-30 | −$4.9M | −$1.3M | — | — |
| Q1 2022 | 2022-03-31 | −$1.5M | −$405,000 | — | −96.70% |
| Q4 2021 | 2021-12-31 | −$2.4M | — | — | −252.93% |
| Q3 2021 | 2021-09-30 | −$1.5M | — | — | −141.92% |
| Q2 2021 | 2021-06-30 | −$3.6M | — | — | −229.67% |
| Q1 2021 | 2021-03-31 | −$1.1M | — | — | −63.67% |
COSCIENS Biopharma free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $6.8M to −$9.2M, a net decrease of $16.0M. COSCIENS Biopharma's latest reported quarter, Q4 2025, generated −$1.5M in free cash flow, an increase of $1.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review COSCIENS Biopharma filings at SEC.gov ↗